202 related articles for article (PubMed ID: 28276427)
1. TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R; Madureira PA; Ferreira B; Baptista I; Machado S; Colaço L; Dos Santos M; Liu N; Dopazo A; Ugurel S; Adrienn A; Kiss-Toth E; Isbilen M; Gure AO; Link W
Nat Commun; 2017 Mar; 8():14687. PubMed ID: 28276427
[TBL] [Abstract][Full Text] [Related]
2. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
4. Tribbles breaking bad: TRIB2 suppresses FOXO and acts as an oncogenic protein in melanoma.
Link W
Biochem Soc Trans; 2015 Oct; 43(5):1085-8. PubMed ID: 26517928
[TBL] [Abstract][Full Text] [Related]
5. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
6. miR-296-3p Negatively Regulated by Nicotine Stimulates Cytoplasmic Translocation of c-Myc via MK2 to Suppress Chemotherapy Resistance.
Deng X; Liu Z; Liu X; Fu Q; Deng T; Lu J; Liu Y; Liang Z; Jiang Q; Cheng C; Fang W
Mol Ther; 2018 Apr; 26(4):1066-1081. PubMed ID: 29525743
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Bhatt AP; Bhende PM; Sin SH; Roy D; Dittmer DP; Damania B
Blood; 2010 Jun; 115(22):4455-63. PubMed ID: 20299510
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
9. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.
Pan CW; Jin X; Zhao Y; Pan Y; Yang J; Karnes RJ; Zhang J; Wang L; Huang H
EMBO J; 2017 Apr; 36(8):995-1010. PubMed ID: 28279977
[TBL] [Abstract][Full Text] [Related]
10. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells.
Zanella F; Renner O; García B; Callejas S; Dopazo A; Peregrina S; Carnero A; Link W
Oncogene; 2010 May; 29(20):2973-82. PubMed ID: 20208562
[TBL] [Abstract][Full Text] [Related]
11. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
12. Nuclear forkhead box O3a accumulation contributing to the proliferative suppression in liver cancer cells by PI3K/Akt signaling pathway.
Hou Y; Sun G; Jiang X; Zhu Z; Yang J
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1124-S1128. PubMed ID: 30539857
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
14. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.
Clement E; Inuzuka H; Nihira NT; Wei W; Toker A
Sci Signal; 2018 Mar; 11(521):. PubMed ID: 29535262
[TBL] [Abstract][Full Text] [Related]
15. Gold Nanocomplex Strongly Modulates the PI3K/Akt Pathway and Other Pathways in MCF-7 Breast Cancer Cell Line.
Mahmoud NN; Abuarqoub D; Zaza R; Sabbah DA; Khalil EA; Abu-Dahab R
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397063
[TBL] [Abstract][Full Text] [Related]
16. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
17. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
Kodigepalli KM; Dutta PS; Bauckman KA; Nanjundan M
FEBS Lett; 2013 Jan; 587(1):5-16. PubMed ID: 23178716
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
19. TRIB2 Stimulates Cancer Stem-Like Properties through Activating the AKT-GSK3β-β-Catenin Signaling Axis.
Kim DK; Kim YN; Kim YE; Lee SY; Shin MJ; Do EK; Choi KU; Kim SC; Kim KH; Suh DS; Song P; Kim JH
Mol Cells; 2021 Jul; 44(7):481-492. PubMed ID: 34326276
[TBL] [Abstract][Full Text] [Related]
20. Applied electric fields suppress osimertinib-induced cytotoxicity via inhibiting FOXO3a nuclear translocation through AKT activation.
Li L; Hu C; Lu C; Zhang K; Han R; Lin C; Zhao S; A C; Cheng C; Zhao M; He Y
Carcinogenesis; 2020 Jul; 41(5):600-610. PubMed ID: 31504249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
